How much does a course of pemetinib cost?

Pemetinib is a new type of targeted therapy specifically targeting cholangiocarcinoma and relapsed or refractory myeloid and lymphoid tumors. It is jointly developed by Incyte Biopharmaceuticals and Innovent Biologics. It mainly acts on fibroblast growth factor receptors (FGFR), especially FGFR2 and FGFR1. By inhibiting the activity of these receptors, pemetinib can effectively prevent the proliferation and spread of tumor cells.

This drug has been approved in China and is widely used to treat adult patients with advanced, metastatic or unresectable cholangiocarcinoma who have undergone systemic treatment and whose tumors have FGFR2 fusion or rearrangement Its remarkable efficacy has been verified in clinical trials, bringing new treatment opportunities to many patients with advanced cancer.

The recommended dose of pemetinib is 13.5mg orally administered daily. It is taken continuously for 14 days and then stopped for 7 days, forming a 21-day treatment cycle. However, as a prescription drug, pemetinib may also cause some side effects, such as diarrhea, fatigue, nausea, etc. Therefore, you must strictly follow your doctor's instructions when using it and monitor your physical condition regularly.

Pemetinib has been launched in China, and patients can purchase it directly from domestic hospitals. The price of the original version of 14 tablets of 4.5 mg is about 30,000 yuan, and a course of treatment costs about about 135,000 yuan. In foreign markets, the price of the original research version13.5mg 14 tablets is as high as about 72,000 yuan, and the price of a course of treatment is about10,800 yuan< span>; The generic version is produced by Lucius Pharmaceuticals in Laos, and the price is very affordable. The same specification only costs 850 yuan, and one course of treatment only costs 1275 yuan or so. For any questions about pemetinib, it is recommended to consult a regular overseas medical company.

Although the price of pemetinib is relatively high, it provides new hope for patients with refractory tumors such as cholangiocarcinoma. With the deepening of scientific research and the advancement of medicine, we expect that pemetinib can be further optimized in the future and bring good news to more patients. At the same time, patients should also pay attention to communicating with their doctors when using it to ensure safe and effective use of this drug.